Minneapolis, MN, Aug. 17, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a novel cardiac electrophysiology (EP) information system, today announced its submission entitled “Enhanced Electrophysiology Recording System” will be presented on Friday, August 19, 2016 at the 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC 2016). The presentation will be held in Pastoral 1 (Session FrCT8) at the Contemporary Resort in Orlando, Florida with a poster session to follow.
Commenting on the milestone, Jay Millerhagen, VP of Clinical Research, said, “We are honored our work was accepted by the editors for the prestigious EMBC 2016 Conference. This submission together with the recent article in JACC: Cardiac Electrophysiology represent significant milestones further validating the PURE EP System’s performance in pre-clinical trials.”
About BioSig Technologies
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $4 billion EP marketplace (1) ( biosigtech.com ). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
The PURE EP(TM) System is a surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system engineered to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the electrophysiologists in identifying ablation targets - areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1), making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig has partnered with Minnetronix on technology development and is working toward a FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation and tested its prototype at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center; and, has performed pre-clinical studies at Mayo Clinic in Minnesota. Additionally, an Advanced Research Program at Mayo Clinic began in June 2016. The Company is also collaborating with other prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UH Case Medical Center in Cleveland, Ohio and Mount Sinai Medical Center in New York.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; AF includes left atrial tachycardia, left WPW, left atrial flutter.
About IEEE EMBC 2016
The 38th Annual International Conference of the IEEE (Institute of Electrical and Electronics Engineers) Engineering in Medicine and Biology Society (EMBC’16) will be hosted at Disney’s Contemporary Resort in Orlando, Florida on August 17-20. The overall theme of the conference is “Empowering Individual Healthcare Decisions through Technology” and will cover diverse topics from cutting-edge biomedical and healthcare technology research and development to clinical applications and biomedical education.
Contact: Investor Relations: Brian McLaughlin BioSig Technologies, Inc. bmclaughlin@biosigtech.com 917-370-9817 Robert Haag Managing Partner IRTH Communications BSGM@irthcommunications.com 866-976-4784
